We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Boehringer’s Pradaxa Gains Additional European Indication

Boehringer’s Pradaxa Gains Additional European Indication

June 6, 2014

Boehringer Ingelheim announced Friday that the European Commission had approved Pradaxa (dabigatran etexilate) to treat and prevent the recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

The FDA approved Pradaxa for the treatment of DVT and PE patients earlier this year.
The approval by the EC comes on the heels of a positive opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency, and is based on results from three phase III clinical trials that established the efficacy of Pradaxa, the German drugmaker said.

Additionally, results from a fourth study demonstrated a reduction of 92 percent in the risk of recurrent blood clots in patients who received Pradaxa compared to placebo. Safety data demonstrated that DVT or PE patients receiving Pradaxa had noticeably lower rates of bleeding compared with those on warfarin, leading to a good overall safety profile, the company said.

Pradaxa has the more clinical trial experience in DVT and PE patients than any other novel oral anticoagulant, BI noted.

DVT and PE can be very dangerous — nearly one in three PE patients dies within three months and 40 percent of patients suffer a repeat blood clot within 10 years of the first one.

The drug also has EU licensure for the primary prevention of venous thromboembolism, a collective term for DVT and PE, in patients who have undergone total knee or hip replacement surgery, BI said. — Kellen Owings

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing